With the bull market in its 10th year, the stock market challenging all-time highs, and assorted economic and political concerns, investors may be considering rotating out of growth stocks and into value stocks – but the author of today’s article advises “value investors had better be very cautious about what sort of ‘value’ they are looking for”, noting that “they often ignore or overlook the signs that a value trap is just about to eat into their assets.” He proceeds to outline “11 specific areas that investors need to consider when it comes to value investing now that the stock market has again challenged new all-time highs.” For more, CLICK HERE.
“Making money on marijuana (cannabis with high content of intoxicating THC) and hemp (cannabis that contains low content of THC) will be extremely difficult — except perhaps in one specific area,” advises the author of today’s article, who outlines where he believes the real money in marijuana won’t be made (growers and pharmaceutical companies, to be exact) and that “one specific area” where he believes it will be made. For more, CLICK HERE.
A railroad operator, a Canadian bank, a global healthcare company with a focus on diabetes care, a tobacco company, and a biotech focused on treatments for unmet medical needs make up the five companies highlighted in today’s article as being undervalued and having grown their earnings per share over a five-year period, with the author noting that “Companies that are growing their earnings are often good investments because they can return a solid profit to investors.” For these five stocks that are attracting the interest of investing gurus, CLICK HERE.
A health care company whose shares are up 57% in the past year and which, unlike many other health care companies, is not threatened by the possibility of a “Medicare for All” type system (in fact, it could actually benefit from a national health insurance model) leads a selection of stocks that have risen sharply (50% or more) in the past 12 months and appear to have the potential for further gains. For these stocks that may be worthy of consideration, CLICK HERE.
The author of today’s article calls it “The F9 Problem”: checking your profit and loss (P&L) statement too often (or not often enough) and making poor decisions (or avoiding taking necessary action) as a result. However, based on a finding published a few weeks ago on Twitter, there may be a solution to this problem – a “sweet spot” for checking your P&L. What is it? CLICK HERE.
You know the saying: Past performance is not indicative of future results. Over a decade ago, the SEC explicitly warned investors about this when it came to mutual funds – and now the author of today’s article is issuing the same warning about “performance chasing” when it comes to ETFs, noting that “Investors who choose funds primarily for their strong track records are often disappointed.” For some specific case studies of ETF performance chasing gone wrong and some pointers on how to avoid falling into the performance chasing trap – including some key performance metrics to watch out for – CLICK HERE.
Despite the market’s recent drop brought on by concerns over escalating trade tensions between the U.S. and China, it is hard for investors to find value plays amongst stocks. There is, however, still value to be had – and today’s article highlights three undervalued stocks to consider. Among them is a mid-cap stock carving out a niche in what the author notes “is the fastest-growing space within the pharmaceutical industry”: oncology. For more on these three value stocks, CLICK HERE.
The yield curve was the focus of much attention – and the source of much concern – when it inverted last month. After all, an inversion of the yield curve has preceded every recession over the past 50 years. However, while the yield curve inverting may be a worrying economic sign, the author of today’s article notes that, while a recession is coming, history indicates it’s not coming tomorrow. Moreover, he asserts that “The recent yield curve inversion is a positive sign for stocks, at least for now.” Why? CLICK HERE.
How can you buy stock directly and bypass using a broker (and paying said broker commission)? With dividend reinvestment plans (DRIPs) – which are being offered by an ever-increasing number of companies. Today’s article highlights “an excellent source of information for those who want to know how to buy stock directly and which companies offer this opportunity” and examines what to be careful of when buying stock directly, who should (and should not) buy stock directly, and more. CLICK HERE.
Tilray, Canopy Growth, Cronos Group and Aurora Cannabis are among the most well-known names among investors in the cannabis space. However, the author of today’s article argues that while “Overall, the longer-term future of the [cannabis] industry actually appears positive as the inevitable consolidations and acquisitions shake-out the weaker players and help build much larger, stronger cannabis companies…that does not mean now is necessarily a good time to buy those stocks.” For his fundamental and technical analysis of these four pot stocks, CLICK HERE.